Proliferative vitreoretinopathy is a blinding condition for which available treatment options do not address the needs of all affected patients. This application's objective is to identify new therapeutic targets and thereby guide development of drugs to prevent and/or treat PVR. Activation of platelet-derived growth factor (PDGF) receptor ??? (PDGFR??) drives experimental PVR, and is associated with this disease in humans. Antioxidants protect rabbits from developing PVR and prevent vitreous-mediated activation of PDGFR??. Furthermore, the unique ability of vitreous to chronically activate PDGFR?? is intrinsic to PVR pathogenesis. Taken together, these observations are basis of our working hypothesis that vitreous persistently activates PDGFR?? by causing an enduring elevation of ROS. In the course of aim 1 we will identify those vitreous-stimulated enzymes that are required to chronically elevate ROS and activate PDGFR??, and we will assess their potential as therapeutic targets. One of the signaling events that are required for experimental PVR is activation of phosphatidylinositol 3 kinase (PI3K). While both PDGFR?? and PDGFR?? activate PI3K in response to vitreous, only PDGFR?? induces PVR. Our working hypothesis is that PDGFR?? unceasingly activates Ras, which is required for persistent and robust activation of PI3K.
In aim 2 of the grant we will deploy a combination of molecular and biochemical approaches to identify those signaling events by which PDGFR?? engages PI3K. Vitreous-induced signaling events trigger cellular responses intrinsic to PVR that include proliferation, contraction, and protection from apoptosis and senescence. For instance, signaling events that constitute pathway #1 are necessary and sufficient for a subset of these cellular responses (protection from apoptosis and senescence). In contrast, while pathway #1 is necessary for proliferation and contraction, it does not suffice.
In aim 3 we will use a combination of molecular and pharmacological approaches to identify the additional signaling events (pathway #2) that are required for vitreous-mediated proliferation and contraction.
The aims of this proposal are:
Specific Aim 1 Determine how vitreous chronically activates PDGFR??.
Specific Aim 2 Investigate the mechanism by which vitreous persistently activates PI3K/Akt.
Specific Aim 3 Identify members of pathway #2, which is required for vitreous-mediated proliferation and contraction. This proposal's central hypothesis is that perpetrators of vitreous-dependent activation of PDGFR?? and downstream signaling events constitute an Achilles heel of PVR. The proposed studies will test this hypothesis by molecularly resolving key signaling events in PVR pathogenesis and assessing if they are viable targets for PVR prophylaxis.

Public Health Relevance

PVR (proliferative vitreoretinopathy) is the primary reason for failure to correct a rhegmatogenous retinal detachment (RRD) (Han, 2008;Ryan et al., 2006). PVR is typically treated surgically, which increases the risk of re-occurrence (Campochiaro, 2006;Charteris, 1998;Glaser et al., 1987);pharmacological treatment options do not exist, despite numerous attempts to develop them (Charteris, 1995). Generating drugs that prevent RRD patients from succumbing to PVR is a major unmet challenge.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
2R01EY012509-14A1
Application #
8628471
Study Section
(DPVS)
Program Officer
Neuhold, Lisa
Project Start
2000-08-01
Project End
2018-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
14
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Schepens Eye Research Institute
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02114
Duan, Yajian; Ma, Gaoen; Huang, Xionggao et al. (2016) The Clustered, Regularly Interspaced, Short Palindromic Repeats-associated Endonuclease 9 (CRISPR/Cas9)-created MDM2 T309G Mutation Enhances Vitreous-induced Expression of MDM2 and Proliferation and Survival of Cells. J Biol Chem 291:16339-47
Pennock, Steven; Kim, Leo A; Kazlauskas, Andrius (2016) Vascular Endothelial Cell Growth Factor A Acts via Platelet-Derived Growth Factor Receptor α To Promote Viability of Cells Enduring Hypoxia. Mol Cell Biol 36:2314-27
Ma, Gaoen; Duan, Yajian; Huang, Xionggao et al. (2016) Prevention of Proliferative Vitreoretinopathy by Suppression of Phosphatidylinositol 5-Phosphate 4-Kinases. Invest Ophthalmol Vis Sci 57:3935-43
Lei, Hetian; Qian, Cynthia X; Lei, Jinghu et al. (2015) RasGAP Promotes Autophagy and Thereby Suppresses Platelet-Derived Growth Factor Receptor-Mediated Signaling Events, Cellular Responses, and Pathology. Mol Cell Biol 35:1673-85
Lei, Hetian; Kazlauskas, Andrius (2014) A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor *. Mol Cell Biol 34:110-22
Pennock, Steven; Haddock, Luis J; Eliott, Dean et al. (2014) Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res 40:16-34
Pennock, Steven; Kim, David; Mukai, Shizuo et al. (2013) Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease. Am J Pathol 182:1659-70
Lei, Hetian; Kazlauskas, Andrius (2013) Detection of H2O2-mediated phosphorylation of kinase-inactive PDGFRα. Methods Enzymol 528:189-94
Vanarsdall, Adam L; Wisner, Todd W; Lei, Hetian et al. (2012) PDGF receptor-ýý does not promote HCMV entry into epithelial and endothelial cells but increased quantities stimulate entry by an abnormal pathway. PLoS Pathog 8:e1002905
Pennock, Steven; Kazlauskas, Andrius (2012) Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses. Mol Cell Biol 32:1955-66

Showing the most recent 10 out of 28 publications